A Study of ETX-19477 in Patients With Advanced Solid Malignancies
Phase 1/2
120
about 2.6 years
18+
14 sites in AZ, CT, FL +10
About this study
Researchers are testing a new drug called ETX-19477 to see if it's safe and effective for people with advanced solid cancers. The trial will involve adults, and the expected duration is 962 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take ETX-19477
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: To characterize the safety and tolerability of ETX-19477, the maximum tolerated dose (MTD) and/or RP2D of ETX-19477
Secondary: To assess the preliminary anti-tumor activity of ETX-19477 in participants by measuring disease control rate (DCR) using RECIST v1.1, To assess the preliminary anti-tumor activity of ETX-19477 in participants by measuring duration of response (DOR) using RECIST v1.1, To assess the preliminary anti-tumor activity of ETX-19477 in participants by measuring objective response rate (ORR) using RECIST v1.1, To characterize the pharmacokinetic (PK) profile of ETX-19477 by measuring elimination half-life (t1/2), To characterize the pharmacokinetic (PK) profile of ETX-19477 by measuring maximum blood concentration (tmax), To characterize the pharmacokinetic (PK) profile of ETX-19477 by measuring maximum plasma concentration (Cmax), To further characterize the pharmacokinetic (PK) profile of ETX-19477 by the Area Under the Blood Concentration-Time Curve (AUC0-t, AUC0-inf), Clearance (CL), Volume of Distribution (Vd)
Oncology